Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Next Previous
Trial Profile

Phase 0/I Study of AMG 232 Concentrations in Brain Tissue in Patients With Recurrent Glioblastoma and of AMG 232 in Combination With Radiation in Patients With Newly Diagnosed Glioblastoma and Unmethylated MGMT Promoters

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 20 Nov 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs AMG 232 (Primary)
  • Indications Glioblastoma; Gliosarcoma
  • Focus Adverse reactions; Pharmacokinetics

    • Most Recent Events

    • 09 Jul 2019 Planned End Date changed from 30 Jun 2019 to 30 Jun 2020.
    • 09 Jul 2019 Planned primary completion date changed from 30 Jun 2019 to 30 Jun 2020.
    • 13 Feb 2019 Status changed from suspended to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Legal

Back to top